ImmunoGenesis, Inc.
Immunotherapy drugs targeting cold tumors resistant to checkpoint inhibitors
- Sector
- Biotech
- Headquarters
- Doylestown, PA
- Founded
- 2019
- Latest Form D
- $5.7M, Jan 2025
- Total capital
- $50.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $50.2M
- 2 Form D · last Jan 2025
- 21 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$5.7M
- Private capital raisedForm D · SEC · 1st filing$44.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Clifford B. StocksDirectorNamed in SEC Form D filings
- Federica O'BrienExecutive OfficerNamed in SEC Form D filings
- Federica PericleExecutive OfficerNamed in SEC Form D filings
- James BarlowExecutive Officer, DirectorNamed in SEC Form D filings
- Jennifer BarlowExecutive Officer, DirectorNamed in SEC Form D filings
- Jeremy BartonExecutive OfficerNamed in SEC Form D filings
Show all 10 people
- Michael CurranDirectorNamed in SEC Form D filings
- Robert SteinDirectorNamed in SEC Form D filings
- Ted KoutouzisDirectorNamed in SEC Form D filings
- Thomas BartonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingAdministration Of Hypoxia Activated Prodrugs And Antiangiogenic Agents For The Treatment Of CancerUSPTOApplication 18935071
- PendingCompositions Comprising Sting Agonists And Methods Of Use For Treating GliomaUSPTOApplication 18760608
- PendingAdministration Of Hypoxia Activated Prodrugs In Combination With Immune Modulatory Agents For Treating CancerUSPTOApplication 16322467
Show all 5 patent records
- Administration Of Hypoxia Activated Prodrugs And Antiangiogenic Agents For The Treatment Of CancerSep 25, 2025 · Application 18935071Pending
- Compositions Comprising Sting Agonists And Methods Of Use For Treating GliomaMay 29, 2025 · Application 18760608Pending
- Administration Of Hypoxia Activated Prodrugs In Combination With Immune Modulatory Agents For Treating CancerDec 2, 2021 · Application 16322467Pending
- Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancerFeb 28, 2019 · Application 15998702Pending
- Compositions Comprising Sting Agonists And Methods Of Use For Treating GliomaApplication 63524349Pending
Related companies, and why
- Axsome Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Response Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Virica Biotech Inc.Similar federal contract value in Biotech · null in contracts
- BIOVEST INTERNATIONAL INCSimilar federal contract value in Biotech · null in contracts
- Cyprium Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Synoligo Biotechnologies, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .